BSX (Boston Scientific Corporation) — AI Stock Analysis & Recommendation

Research of August 31, 2026 · Healthcare / Surgical & Medical Instruments & Apparatus

TradeFlare's AI research teams rate BSX a BUY. The latest price is $43.31.

The research plan

• Entry: $48.30
• Target: $57.96
• Stop: $40.95
• Time horizon: weeks

The insider buying suggests a medium-term conviction in the company's recovery and growth prospects.

Why

The insider buying suggests a medium-term conviction in the company's recovery and growth prospects. Catalysts to watch: Significant undervaluation relative to peers and industry averages, supported by a low PEG ratio; Strong 'buy' consensus from analysts with a substantial implied upside target price; High-conviction insider buying from an executive, signaling confidence in the company's future. Key risks: Recent cyberattack has disrupted operations and highlights cybersecurity vulnerabilities; Potential for product liability issues and ongoing regulatory scrutiny inherent in the medical device industry; High historical volatility and a deep recent drawdown indicate significant market risk.

What could push BSX higher

• Significant undervaluation relative to peers and industry averages, supported by a low PEG ratio.
• Strong 'buy' consensus from analysts with a substantial implied upside target price.
• High-conviction insider buying from an executive, signaling confidence in the company's future.

Key risks for BSX

• Recent cyberattack has disrupted operations and highlights cybersecurity vulnerabilities.
• Potential for product liability issues and ongoing regulatory scrutiny inherent in the medical device industry.
• High historical volatility and a deep recent drawdown indicate significant market risk.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Boston Scientific (BSX) presents a compelling bullish case driven by its significant undervaluation relative to peers and growth prospects, as indicated by its low PEG ratio and strong analyst consensus. Despite recent headwinds and a slight dip in quarterly cash flow, the company's robust TTM free cash flow, high margins, and strong market position provide a solid foundation for future growth, justifying a...

• BSX's trailing P/E of 19.55x is significantly lower than its peer average (41.2x) and the US Medical Equipment industry average (26.9x).
• The PEG ratio of 0.67 suggests that BSX is undervalued relative to its expected earnings growth.
• Analyst consensus indicates a strong 'buy' recommendation with a mean target price of $62.69, implying a substantial upside from the current price.

Technical team: Neutral

The analysis presents a neutral consensus due to conflicting signals, particularly between the bearish momentum indicators and the sideways price action. While there's a potential for a short-term bounce towards resistance, the lack of conviction in volume and the bearish momentum signals warrant caution. The stock is currently trading near support, offering a defined risk/reward if a bounce materializes.

• Price is consolidating near support, with a potential for a short-term bounce towards the immediate resistance level of $49.40.
• The stock is trading in a sideways range with low volume, suggesting a neutral outlook until a clear breakout or breakdown occurs with increased volume.
• Bearish momentum is indicated by MACD and the current price being below resistance, despite oversold conditions in the Stochastic Oscillator.

Sentiment team: Neutral

The overall sentiment for BSX is neutral, reflecting a balance between ongoing operational concerns like a cyberattack and reduced guidance, and underlying positive factors such as potential undervaluation and long-term healthcare growth drivers. Sentiment momentum is stable as conflicting signals from various sources keep the outlook mixed.

• Boston Scientific's news sentiment is neutral, balancing concerns over a cyberattack, guidance reduction, and product recall against potential undervaluation and positive retail investor sentiment
• Boston Scientific (BSX) exhibits a neutral overall sentiment, with conflicting signals from news headlines and social media, highlighting both growth potential in the healthcare sector and significant concerns stemming from a cyberattack and revised guidance
• Boston Scientific exhibits a neutral sentiment due to conflicting signals from recent downgrades and product headwinds, offset by potential undervaluation, strong institutional ownership, and broader healthcare growth trends. Consensus: NEUTRAL

Risk team: High

BSX presents a high-risk profile due to significant cybersecurity vulnerabilities, product liability concerns, and intense market competition within the medical technology sector. The stock's history of deep drawdowns and high volatility further amplifies these risks, necessitating a cautious approach.

• Cybersecurity Vulnerability: A recent cyberattack disrupted global IT systems, highlighting significant operational and financial risks, including impacts on order processing and shipments.
• Product Liability and Regulatory Scrutiny: As a medical device company, BSX faces substantial risks from product liability lawsuits and evolving regulatory landscapes concerning device safety and efficacy.
• Deep 1-Year Drawdown and High Volatility: The stock has experienced a significant drawdown of over 60% in the past year, coupled with high annualized volatility, indicating substantial price swings and potential for further downside.

BSX at a glance

Market value	$61.4B
Price / earnings	17.0
Revenue growth (year over year)	13.5%
Profit margin	17.5%
Debt / equity	0.44

Every AI call on BSX since May 25, 2026, and what happened next (7 calls) →

Research of August 31, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.